The stock of Revolution Medicines Inc (RVMD) has seen a 4.66% increase in the past week, with a -4.72% drop in the past month, and a 12.36% flourish in the past quarter. The volatility ratio for the week is 2.99%, and the volatility levels for the past 30 days are at 3.83% for RVMD. The simple moving average for the past 20 days is 1.35% for RVMD’s stock, with a 33.40% simple moving average for the past 200 days.
Is It Worth Investing in Revolution Medicines Inc (NASDAQ: RVMD) Right Now?
Additionally, the 36-month beta value for RVMD is 1.44. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RVMD is 138.72M and currently, short sellers hold a 11.64% ratio of that float. The average trading volume of RVMD on August 21, 2024 was 1.48M shares.
RVMD) stock’s latest price update
Revolution Medicines Inc (NASDAQ: RVMD) has experienced a rise in its stock price by 2.80 compared to its previous closing price of 43.35. However, the company has seen a gain of 4.66% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-11 that Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Ryan Asay – Senior Vice President of Corporate Affairs Mark Goldsmith – Chairman and Chief Executive Officer Jack Anders – Chief Financial Officer Steve Kelsey – President of R&D Wei Lin – Chief Medical Officer Conference Call Participants Marc Frahm – TD Cowen Michael Schmidt – Guggenheim Eric Joseph – JPMorgan Jonathan Chang – Leerink Partners Chris Shibutani – Goldman Sachs Eliana Merle – UBS Alec Stranahan – Bank of America Kelly Shi – Jefferies Jay Olson – Oppenheimer Laura Prendergast – Raymond James Joseph Catanzaro – Piper Sandler Operator Good day and thank you for standing by. Welcome to Revolution Medicine’s Q2 2024 Earnings Conference Call.
Analysts’ Opinion of RVMD
Many brokerage firms have already submitted their reports for RVMD stocks, with Needham repeating the rating for RVMD by listing it as a “Buy.” The predicted price for RVMD in the upcoming period, according to Needham is $62 based on the research report published on July 16, 2024 of the current year 2024.
Barclays, on the other hand, stated in their research note that they expect to see RVMD reach a price target of $52. The rating they have provided for RVMD stocks is “Overweight” according to the report published on July 12th, 2024.
Jefferies gave a rating of “Buy” to RVMD, setting the target price at $63 in the report published on July 08th of the current year.
RVMD Trading at 5.53% from the 50-Day Moving Average
After a stumble in the market that brought RVMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.33% of loss for the given period.
Volatility was left at 3.83%, however, over the last 30 days, the volatility rate increased by 2.99%, as shares sank -3.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.78% upper at present.
During the last 5 trading sessions, RVMD rose by +5.58%, which changed the moving average for the period of 200-days by +112.55% in comparison to the 20-day moving average, which settled at $43.89. In addition, Revolution Medicines Inc saw 55.38% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RVMD starting from Kelsey Stephen Michael, who sale 16,667 shares at the price of $42.98 back on Aug 13 ’24. After this action, Kelsey Stephen Michael now owns 269,073 shares of Revolution Medicines Inc, valued at $716,389 using the latest closing price.
STEPHEN M. KELSEY, the Officer of Revolution Medicines Inc, proposed sale 16,667 shares at $42.98 during a trade that took place back on Aug 13 ’24, which means that STEPHEN M. KELSEY is holding shares at $716,348 based on the most recent closing price.
Stock Fundamentals for RVMD
Current profitability levels for the company are sitting at:
- -809.61 for the present operating margin
- -13.24 for the gross margin
The net margin for Revolution Medicines Inc stands at -699.74. The total capital return value is set at -0.35. Equity return is now at value -40.73, with -36.03 for asset returns.
Based on Revolution Medicines Inc (RVMD), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -5.83. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -64.67.
Currently, EBITDA for the company is -477.88 million with net debt to EBITDA at 0.32. When we switch over and look at the enterprise to sales, we see a ratio of 9822.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.42.
Conclusion
In conclusion, Revolution Medicines Inc (RVMD) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
